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1 These recommendations are based on guidelines published jointly by the Centers for Disease Control (CDC) and the American 
Thoracic Society (ATS): Am J Resp Crit Care Med 2000;161:S221-43;  MMWR June 9, 2000 Vol 49, No RR-6: 1-51, MMWR 
Aug 31, 2001 Vol 50, No 34, 733-735, and MMWR August 8, 2003  Vol 52; 735-739.   Copies of TB-related statements 
published in MMWR are available through the Division of Tuberculosis Prevention and Control, MDPH (617-983-6970) 
and through the CDC site on the World Wide Web (www.cdc.gov/nchstp/tb/). 
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I.  Testing for Latent TB Infection  
 
Question 1.  What is latent tuberculosis infection (LTBI)? 
 
The term Latent Tuberculosis Infection (LTBI) defines an asymptomatic state in persons who are 
infected with Mycobacterium tuberculosis and have no clinical or radiographic evidence of 
active disease. The organism resides within the host in a clinically inactive, or latent, state, 
contained by the host immune response. Latent TB infection currently is detected by a 
standardized, intradermal skin test, termed the tuberculin skin test (TST), -- or by a blood test 
(QuantiFERON-Gold® or -Gold-In-Tube®, or T-Spot®.TB), persons with risk factors for 
exposure to TB. For persons with untreated latent TB infection and intact immunity, the 
estimated risk of developing tuberculosis disease is 5% to 10% over a lifetime, with about 50 – 
80% of that risk occurring during the first 2 years following infection. For persons who are 
immunocompromised by HIV co-infection, the risk of developing disease increases to 5% to 
10% per year.  
 
Active TB disease rarely is discovered in asymptomatic persons by tuberculin skin testing. 
However, finding LTBI provides an opportunity to treat and prevent reactivation of the latent 
infection that leads to active disease. Studies have shown that treatment of LTBI can prevent 
reactivation TB with an efficacy of 60%-90%. Because of the relatively low TB prevalence in 
the United States, and with reactivation tuberculosis representing a large proportion of new 
cases, treatment of LTBI is considered an important public health strategy to achieve national 
TB elimination. Latent TB infection generally is not treated in high-prevalence countries, 
because detection and complete treatment of active disease is the top personal and public health 
priority. One exception is children who are contacts of known active cases; they are usually 
tested and treated even in high-prevalence countries. 
 
 
Question 2.  What is the best test for LTBI, and how should test results be recorded? 
  
Tuberculin skin testing with intermediate strength (5 TU – “Tuberculin Units”) purified protein 
derivative (PPD), administered by the Mantoux intradermal technique (not by multiple puncture 
devices, such as Tine® or Mono-Vacc®), is the current standard test for detecting LTBI. The TST 
is administered by injecting 0.1 ml (5 TU) PPD solution intradermally (not subcutaneously), 
usually into the ventral surface of the forearm. Forty-eight to 72 hours after the test is 
administered, the diameter of palpable or visible induration (raised swelling) is measured 
transverse to the long axis of the arm (i.e. across the arm) and recorded in mm.2  Note: redness 
without induration should be ignored. Reading of the TST should be performed by a person who 
is adequately trained in its interpretation; patients, or parents of patients, should NEVER be 
permitted to read their own skin tests.  
 
                                                 
2 Three reading methods have been recommended. With one method, the arm is positioned so that a light shines tangentially over 
the skin reaction, highlighting any induration. The lateral edges of the visible induration are marked with a pen and measured 
with a millimeter (mm) ruler. With the second method, the lateral edges of the induration are determined by moving a ballpoint 
pen across the arm from each side until resistance is met. A mark is made and the diameter is measured with a mm ruler.  The 
third method involves direct palpation of the induration, marking the edges and measuring the distance across the forearm. With 
any of these methods, only the measurement transverse to the long axis of the arm (not two dimensions) is recorded. 
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Caution:  The Massachusetts Department of Public Health and others have received multiple 
reports of false-positive reactions using Aplisol® (Squibb), one of the 2 brands of tuberculin skin 
testing reagent currently licensed in the US. Therefore, Tubersol® (Connaught) is the only 
agent recommended by MACET for tuberculin skin testing in Massachusetts. 
  
Interferon-gamma Release Assays (IGRA's): QuantiFERON-Gold®, QuantiFERON-Gold-In 
Tube®, and T-Spot TB® are new tests approved by the FDA for detection of latent TB infection, 
in certain circumstances. The QuantiFERON laboratory tests use an ELISA to measure the 
production of interferon-gamma by whole blood leukocytes incubated with protein antigens 
specific to M tuberculosis complex and a few other nontuberculous mycobacteria -- but NOT by 
bacilli Calmette-Guerin (BCG). The T-Spot also uses MTb-specific antiges, but it employs an 
elispot format to quantify the number of T cells that are secreting interferon-gamma. These tests 
require a single patient visit for a blood draw, and results are reported as a positive or negative 
laboratory value. Special processing of the blood cells and plasma by trained laboratory 
personnel is necessary. Following its published indications, these tests are an acceptable 
substitute for the TST in Massachusetts. Guidelines for the use of the earlier generations of the 
QuantiFERON tests were published by the Centers for Disease Control (CDC) in 2003 and 2005; 
these currently (as of January, 2009) are in-revision to accommodate the newer generation 
QuantiFERON-Gold-In Tube test and T-Spot TB. MACET has published an interim set of 
guidelines for the use of the IGRA's (ref: 
http://www.mass.gov/Eeohhs2/docs/dph/cdc/tb/alerts_igra_guidelines_diagnose_infection.pdf) 
 
Question 3:  Who should be tested for LTBI in Massachusetts? 
 
Testing for LTBI should be reserved for persons who meet some or all of the following criteria: 
• Are at high risk of TB infection (see Question 4).  
  and 
• If infected, are at high risk of developing active TB. 
  or 
• f they developed active TB, would place vulnerable contacts at risk. I
 
uestion 4:  Who is at high risk of TB in Massachusetts today? Q
 
High-risk persons in Massachusetts who should be tuberculin skin tested include: 
• Close contacts of known active pulmonary TB cases, or persons working or residing in 
congregate settings (shelters, jails, and some health care facilities) considered high-risk 
for TB. 
• Non US-born persons from high-prevalence countries who have been in the US 5 years 
or less, or persons with extended (> 1 month) travel to these countries within the past 5 
years.3 
 
 
                                                 
3 High prevalence places from which Massachusetts TB cases have come in recent years include, but are not limited to, China, 
Southeast Asia, India, Haiti, Dominican Republic, Central America, Brazil, Russia, and sub-Saharan Africa. TB case rates have 
almost tripled in the former Soviet Union in the decade following its’ dissolution, and an increasing number of arrivals are 
expected. http://www.mass.gov/dph/cdc/tb/ 
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• Persons with fibrotic abnormalities on chest x-ray4 consistent with previous TB. 
Persons with clinical conditions associated with progression to active TB, such as HIV 
infection, silicosis, diabetes, chronic renal failure/hemodialysis, gastrectomy, jejunoileal 
bypass, solid organ transplantation (r
• 
enal, cardiac), carcinoma of the head and neck, and 
 underweight. 
• 
t that 
 Immunocompromised persons (e.g. HIV, chronic corticosteroid use, administration of 
rs.  Note: We have developed a questionnaire that can be used in 
clinical settings to help determine a child’s risk of tuberculosis and the need for a tuberculin 
uestion 5:  Should persons who have been vaccinated with BCG be tested for LTBI, and if 
nge from no 
being more than 15%
• Injection drug users. 
Children who meet these criteria or who have been in regular contact with high-risk 
adults with LTBI also are considered at risk (see footnote 7).  This is not to sugges
persons with LTBI are themselves infectious, but they may indicate other, active, 
infectious persons in the environment.  
•
TNF-α inhibitors or receptor blockers) with risk(s) for TB exposure. 
 
Note: In the ATS/CDC Guidelines referenced on p. I-1, Tables 2 and 3 indicate risk estimates 
for these and other facto
skin test (Appendix 1).  
 
Q
tested, how should the results be interpreted?   
 
BCG is administered to more than 80% of children in the world as part of the Extended Program 
on Immunization.  The vaccine is given primarily in countries with rates of LTBI much higher 
than those found in the US or Western Europe, and many persons who have previously received 
BCG also may have LTBI.  Reactions to the TST following BCG vaccination may ra
induration to >10 mm, although many are in the 5-9 mm range.  These reactions gener
with time, though their size can be affected by the age at vaccination, the number of 
vaccinations, and the number and frequency of subsequent tuberculin skin tests since 
vaccination. Persons who have received BCG should be tested for LTBI as clinically indicat
positive test results in persons who have had contact with a case of TB or who come from a 
country with a high rate of TB should be assumed to be due to TB infection, not BCG, and 
treatment should be recommended, unless contraindicated. A rule of thumb states that TST 
reactions of 15 mm or greater are likely to be TB, as are reactions of 10 mm or greater in persons 
immunized more than 15 years ago. Some persons who had been vaccinated with BCG and
not believe the
ally wane 
ed; 
 do 
 results of a positive TST signals TB infection may be tested with an IGRA which, 
y nature of the antigens used for the tests, have greater specificity for MTb infection (see 
uestion 6:  Which persons, if they develop active TB, pose an especially high risk to the 
 
gregate setting with 
                                                
b
Question 2).   
 
Q
community? 
 
Persons with active TB who may threaten the public’s health include anyone  with infectious TB
(usually pulmonary and/or laryngeal TB) who is working or living in a con
 
4 Prior tuberculosis disease can have a variety of nonspecific appearances.  However, radiographically dense, upper lobe linear or 
nodular changes are characteristic. Hilar, lower lobe, and pleural densities are also seen, but are less specific for TB.  For 
example, in the Ohio River Valley, hilar calcifications are more likely to represent previous histoplasmosis than TB. Apical 
pleural thickening without parenchymal scarring is specifically not associated with TB. 
Latent Tuberculosis Infection (LTBI) – Targeted Testing and Treatment / page - 5 
vulnerable persons, such as HIV/AIDS or otherwise-immunocompromised patients, the elderly, 
uestion 7:  What tuberculin skin test (TST) induration diameter is considered indicative  
nts define ranges of reaction size for a positive TST: 5 mm, 10 mm, or 15 mm, 
dep d
detailed
•  
ease. In this group, detecting all TB infections is considered 
tive reactions. Four  high-risk 
 pulmonary or laryngeal cases. 
d, 
one, or equivalent, daily for 1 month or longer). Note: Inhaled 
 immune system to 
• 
fection or disease. Included in this group are 
ive 
e footnote 3). 
ousing, medically 
resided for extended periods in congregate settings known to    
ransmission, such as shelters, jails, prisons, and detoxification or 
 disease, or engaged in high-risk procedures such as 
riology laboratory work, or work 
• 1
y as 3 
                                                
homeless persons, newborn babies, and children 4 years of age and under. 
 
Q
of TB infection?   
 
Three cut-off poi
en ing on the risk of TB infection or disease in the individual or population being tested, as 
 below.  
5 mm or greater TST induration: is considered positive only in persons at highest risk
for infection or active dis
more important than the risk of including some false posi
subgroups are included: 
- Close contacts of active
- HIV-immunocompromised persons (the risk of progression to active TB, if TB infecte
is 5% to 10% per year). 
- Organ transplant recipients or other immunosuppressed persons (including persons 
receiving long-term, high dose oral or parenteral corticosteroid therapy (arbitrarily 
defined as ≥ 15 mg prednis
corticosteroid use is not associated with sufficient suppression of the
reduce the TST response.  
- Persons with fibrotic chest x-ray findings consistent with old TB. 
10 mm or greater TST induration: Such tests are considered positive for persons 
known to be at high risk for in
- Non US-born persons from high-prevalence countries who have been in the US f
years or less (se
- Disadvantaged low-income persons (malnutrition, crowded h
underserved).  
- Persons over age 70 and children 4 years of age and under.  
- Persons residing or having 
be associated with TB t
drug-rehabilitation centers. 
- Injection drug users. 
- Health care workers and other workers in facilities serving populations at increased 
risk of unsuspected TB
bronchoscopy, sputum induction, autopsies, mycobacte
in homeless shelters.5
- Other high-risk professions, such as mortuary work.6
5 mm or greater TST induration: 
- Persons at low risk of TB infection, for whom TST is generally not indicated, are more 
likely to have false-positive reactions if a 10 mm cut-off is used, due to non-specific 
hypersensitivity to environmental mycobacteria.  It has been estimated that as man
 
5 Health care facilities and other Massachusetts workplaces covered under the Occupational Services Health Administration 
(OSHA) regulations should follow current OSHA directives regarding TST testing, interpretation, and treatment. 
6 Out-of-date local or state regulations have required food-handlers, hairdressers and other workers not at increased risk to be 
tested for TB. Ideally, testing should be avoided, but if required, the 15 mm cut-off should be used unless other risk factors 
apply.  The Massachusetts law mandating pre-employment tuberculin skin testing for all school personnel was repealed in 2003. 
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out of 4 TST indurations of 10 mm to 14 mm in low-risk persons are not due to TB. By
increasing the cut-off size to 15 mm in low-risk persons, sens
 
itivity decreases but 
specificity increases. School children in Massachusetts, unless they have specific risk 
factors for TB, should no longer be routinely tested for TB.7
 a 
e (some 
t testing, at a 
equency determined by the estimated risk, or by regulations, such as those issued by 
A). 
 not been infected with TB. However, repeated skin 
testing can cause the false impression of recent infection (TST conversion) in persons who had 
 
rs 
 does not 
ses 
r Tuberculosis and Tuberculosis Infection in High-Risk 
losis  
MWR 44:18-34, September 8, 1995;  
ttp://www.cdc.gov/mmwr/preview/mmwrhtml/00038873.htm
 
 
Question 8.  Who should be retested for LTBI in Massachusetts? 
  
Only those with a negative skin test and ongoing risk of exposure to TB should be retested.  In
low-prevalence state like Massachusetts, relatively few people are included in this category.  
Close contacts of known, infectious TB cases, persons likely to be exposed by travel in high-
prevalence regions of the world, and persons who work at jobs associated with exposur
health care workers, shelter workers, correction officers, etc.) should have repea
fr
institutions or by the Occupational Safety and Health Administration (OSH
 
Question 9.  Can repeat skin testing for TB cause a positive reaction? 
 
No. The administration of a tuberculin skin test cannot, by itself, cause reactivity to future 
tuberculin skin testing in persons who have
actually been infected in the remote past.  
In the absence of subsequent stimulation , TST reactivity wanes over a period of many yea
following TB infection. This fading of “immune memory” for the antigens in PPD may give a 
falsely-negative result following the administration of a single TST years after the initial 
infection. However, the host’s immune memory for PPD can be boosted by the first TST after 
many years, so that the subsequent TST reaction size may be significantly larger than on the 
initial test, even if no further exposure to TB has occurred. The repeat TST in such cases thus 
may appear to have converted from negative to positive. However, the boosted reaction
reflect recent infection; rather, it represents stimulated immune memory for past infection.  In 
persons who are to undergo serial tuberculin skin testing (as may be required in some 
circumstances, such as for high-risk employees of certain health care facilities; see Question 10, 
below), using a 2-step baseline skin test procedure and using a change in induration of 10 mm as 
criteria for conversion, are recommended steps to minimize boosting and the incorrect diagno
of skin test conversions. See Screening fo
Populations.  Recommendations of the Advisory Council for the Elimination of Tubercu
(M
h ) for further discussion. 
                                                
 
 
Question 10.  What is 2-step tuberculin skin testing, and when is it indicated?  
 
 
7 Tuberculosis testing of school children should be based on individual risk factors (see Question 4), not the location of their 
school or residence.  MACET has developed a questionnaire (see Appendix 1) to assist pediatricians determine which children 
should be tested.  Copies are available through the Massachusetts Department of Public Health, Division of Tuberculosis 
Prevention and Control (617-983-6970). 
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False TST conversions due to boosting of waning hypersensitivity to the antigens contained in 
PPD (see Question 9) can be reduced by administering a 2-step baseline skin test – in those 
increasingly uncommon circumstances when repeated TB skin testing is indicated by the high 
risk of ongoing infection (e.g., some health care workers).  This applies only to person who have 
 a TST in the recent past (i.e. this may be defined arbitrarily within a period of years 
 10 years, for example).  It is generally not required for 
e 
nd, again, 
nge is 
si  
increase in reaction size of 10 mm or more from the baseline 
action is considered a true conversion (i.e. indicating infection has occurred since the previous 
ST), and should warrant evaluation for active disease. If active disease is not found, treatment 
I. Treatment of Latent TB Infection 
infe atment, if they also fulfill the following criteria: 
• omplete a full course of therapy (treatment of LTBI is not mandatory, even if 
• 
ess 
n increase 
I? 
                                                
not received
long enough for immunity to wane – 5 to
young people, arbitrarily those under age 20, for example.  
Procedure: 
1. Administer the first TST, as usual. 
2. If the first TST is positive (according to the risk-based criteria – answer to question 9), th
subject is considered TB-infected, and further skin testing is not warranted. 
3. If the first TST is negative, a second TST is done (one week to one month later) a
it is read at 48-72 hours.  This second reading may be larger than the first (a 10 mm cha
con dered significant), due to boosting.  If positive, the subject is considered TB-infected and
evaluated for LTBI treatment.  If still negative, this second test becomes the baseline 
measurement (i.e. mm induration) against which future skin test results are compared. 
4. On subsequent testing, an 
re
T
of LTBI should be considered. 
 
 
I
 
Question 11:  Who should be treated for latent TB infection? 
 
Anyone at high risk for progression to TB who has a positive tuberculin skin test for TB 
ction is a candidate for tre
• No symptoms, signs, or radiographic evidence of active TB.8 
Willing to c
strongly recommended).  
Available to be clinically monitored by a health care provider during the full course of 
treatment.  
• No medical contraindications to treatment, such as severe liver disease, drug 
hypersensitivity, or medical conditions that make adherence unlikely, such as mental illn
or alcoholism.  
 
Where available, supervised treatment or directly observed treatment ( DOT) ca
dherence for high-risk persons. a
 
 
Question 12:  What are the currently recommended treatments for LTB
 
8 In the absence of symptoms suggesting pulmonary or extrapulmonary TB, only the history, physical examination, and chest x-
ray should be part of a clinical work-up for LTBI.  Other tests, such as sputum or urine culture, have an extremely small yield, 
and are subject to false-positive results if done routinely.  The erythrocyte sedimentation rate (ESR) is neither sensitive nor 
specific for active TB. 
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In the past, only isoniazid (INH) was recommended for treatment of LTBI, but now there are 3 
treatme clude INH: 
 
Option
• eptance and long-term 
adherence) and its potential for hepatotoxicity, especially for persons over age 35 years.9 
r 
Opt
• 
ities 
 
Option
• 
 
patients with silicosis in Hong Kong. Am. 
. 
or 
 Boston's homeless. Am J Respir Crit Care Med. 154:1473-7, 1996). 
• 
l therapy used for 
• 
 rant adults or for contacts of known INH-resistant cases. A 
                                                
nt options, 1 of which is rifampin-based and does not in
 1. INH daily (self-administered or by DOT), or twice-weekly (by DOT), for 9 months 
• Considered the optimal treatment in terms of efficacy. 
May be limited by its long duration (may discourage initial acc
• Recommended for children10 and adults, with or without HIV co-infection, and with o
without fibrotic chest x-ray abnormalities suggesting old TB. 
 
ion 2. INH daily (self-administered or by DOT), or twice-weekly (by DOT) for 6 months 
Considered sub-optimal compared to the 9-month INH treatment because it is less 
effective. 
• Advantages over the 9-month INH treatment: Greater initial acceptance and long-term 
adherence may be more likely, and marginally less hepatotoxicity than the 9-month 
regimen. Potential for hepatotoxicity increased for those over age 35 years (see footnote 
9).  
• Recommended for adults without HIV co-infection and without chest x-ray abnormal
suggesting old TB. 
 3. Rifampin alone for 4 months.  
Efficacy considered comparable to the 6-month INH treatment, but few studies have 
examined the efficacy of rifampin as a single agent for the treatment of LTBI (refs: Hong
Kong Chest Service, Tuberculosis Research Centre, Madras, and British Medical 
Research Council. 1992. A double-blind placebo controlled clinical trial of three 
antituberculosis chemoprophylaxis regimens in 
Rev. Respir. Dis. 145:36—41; Polesky A. Farber HW. Gottlieb DJ. Park H. Levinson S
O'Connell JJ. McInnis B. Nieves RL. Bernardo J. Rifampin preventive therapy f
tuberculosis in
• Shorter duration than INH; less hepatotoxicity. 
Limited by potential interactions of rifampin with many other medications, including 
birth control pills and hormonal implants11 and anti-retrovira
HIV/AIDS.12 
Rifampin may cause false-positive urine test for opiates, which may be an important 
consideration in cases involving some types of workers who may be subject to routine 
testing (such as bus drivers or law enforcement personnel). 
Useful option for INH -intole•
recent review strongly suggests wider use of this regimen because of its short duration 
and safety (Reichman, LB, Lardizabal, A, Hayden, CH. Considering the role of four 
 
9 INH hepatotoxicity is age-related, with increasing rates over age 35 years. (See Question 15). 
10 INH for 9 months is the only regimen recommended for treatment of children with LTBI at this time. 
11 An alternative method of birth control (e.g. a barrier method, such as condoms) must be used by heterosexually-active women 
to avoid pregnancy. 
12 Interactions between rifamycins and drugs used in HIV treatment are complex (see Question 15). 
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months of rifampin in the treatment of latent tuberculosis infection. Amer J Respir Crit 
Care Med. 170:832-5, 2004. 
 
OTE: The recommendation for a 2 month regimen of rifampin plus pyrazinamideN  (2RZ), 
cause of 
its unacceptably high rate of hepatotoxicity. The 2 month rifampin plus pyrazinamide 
originally made in the April, 2000, ATS/CDC Guidelines, has been withdrawn be
regimen should not be used in either HIV-negative or HIV-positive persons for treatment 
 
Qu i hich treatment regimen to choose for my patient? 
 
Choosi
• 
e efficacious than either 6-month INH or the 4 month rifampin.  
• 
ted 
 
en 
ng for 
y during pregnancy and for at least 3 months postpartum is warranted in 
ntial drugs 
ed, especially during the first trimester.  However, HIV infection and 
a 
• 
, 
 old 
k 
 any 
nce, 
of LTBI  ( MMWR  52(31), 735-739, August 8, 2003 ). 
est on 13:  How do I decide w
ng a treatment regimen is based on several considerations, such as 
Efficacy:  All 3 treatments are considered efficacious, although the 9-month INH 
regimen is considered mor
Medical considerations: 
- Active liver disease, history of previous hepatitis, or factors predisposing to liver 
disease such as alcoholism, injection drug use, and use of prescription drugs associa
with liver toxicity: postpone or reconsider therapy.  Rifampin is associated with less 
hepatotoxicity than INH.  
- Essential medications that interact with rifampin (including some HIV therapy, see 
footnote 12):  avoid rifampin, postpone, or reconsider treatment. 
- Birth control pills and hormonal implants: avoid rifampin or find alternative birth
control (e.g. barrier method, such as condoms). 
- Pregnancy: INH and rifampin are considered safe (category C) during pregnancy, wh
necessary; vitamin B6 is recommended with INH during pregnancy. Close monitori
hepatotoxicit
women treated for LTBI. Many providers and patients prefer to postpone elective 
treatment for LTBI until after pregnancy on the general principal that non esse
should be avoid
recent TB exposure with TST conversion are strong indications for therapy during 
pregnancy.  
- Breast feeding: not a contraindication to therapy. Although drugs may be secreted in 
breast milk, no adverse effects from these drugs on nursing infants have been 
demonstrated.  
• Logistical considerations:  Persons who will be moving from the area or who are in 
supervised setting for a limited duration (e.g, college students, detox, rehabilitation, 
prison) may be more appropriate for a shorter regimen.  Persons who can be supervised 
over a longer period (e.g, in prisons) may be given the 9-month INH treatment regimen 
with less fear of non-adherence. 
Age:  Risk of INH-induced hepatitis increases with age (see footnote 9). Previous 
ATS/CDC recommendations limited INH to persons under age 35 years; for persons 
older than 35 years of age, treatment was recommended only when other risk factors
such as recent TST conversion, HIV co-infection, or x-ray abnormalities suggesting
TB, were present. The current ATS/CDC recommendations assume that only high-ris
persons are tested, and therefore, treatment with INH and /or rifampin is warranted at
age. In reality, however, considerable administrative testing (required for job cleara
immigration, etc) still occurs among persons at low-risk for TB. Of the 3 approved 
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treatment regimens for LTBI, 4 months of daily rifampin alone may have the least 
hepatotoxicity for those over age 35. 
• Cost: INH is less expensive than rifampin alone. However, shorter course regimens 
generally require fewer office visits (see Question 15: Monitoring, below).  Drug 
intolerance, drug interactions, and laboratory tests are among the other costs to be 
considered. In Massachusetts, treatment for LTBI is available free of charge through
Massachu
 the 
setts Department of Public Health’s TB clinic system.  
) daily for 4 months. Current preparations of INH in suspension 
Question 14:  What are the appropriate dosages for the 3 LTBI treatment options, and how 
should
 
The do
deta  
• 
rhea). 
• g capsules) 10 mg/kg (600 mg, max) daily or twice weekly 
(unlike twice weekly INH, dose is not increased).  Not recommended for treatment of 
 
Questi
 
Regula
education, to encourage adherence, and to increase safety.  Recom
with th
• INH
stro
Ma n a one-month 
dru ssment. 
The
- with 
s rate of only 0.1% among patients; the majority of patients in this study were 
under age 35 years (JAMA 1999  281; 1014-18. Full text available at: 
                                                
• Patient choice: In the absence of factors dictating one regimen or another, patients often 
have strong opinions about taking one INH tablet daily for 6 or 9 months, or 2 rifampin 
capsules (typical doses
 
are based in sorbital, and at doses indicated for older children and adults can cause 
diarrhea. 
 
 they be prescribed? 
sages are listed below. Please refer to the official CDC/ATS guidelines for additional  
ils (Table 8, ATS/CDC LTBI Statement, AJRCCM 2000). 
INH: (50, 100, 300 mg tablets; 50 mg/5 ml oral suspension) 
g- Adults: 5 m /kg (300 mg, max) daily, or 15 mg/kg (900 mg, max) twice weekly. 
- Children: 10-20 mg/kg (up to 300 mg) daily, or 20-30 mg/kg twice weekly (up to 900 
mg) twice weekly (see response to Question 13, above, re. INH suspension and diar
Rifampin: (150, 300 m
LTBI in children. 
• Rifabutin:13 (150 mg capsules) 5 mg/kg (300 mg max) daily or twice weekly (rifabutin 
daily or twice weekly is reduced to 150 mg when used in combination with   some 
antiretroviral agents.  
 
on 15:  How should I monitor safety and adherence during LTBI treatment? 
r monitoring of treatment for LTBI is performed for 3 purposes:  to reinforce patient 
mended monitoring varies 
 e 3 regimens: 
 (9- and 6-month regimens):  Monthly visits to a trained health care provider are 
ngly recommended during INH therapy. It is the standard-of-care for all 
ssachusetts TB clinics. Patients are given a prescription for no more tha
g supply, and this prescription is re-filled following each monthly clinical asse
 main complications of INH therapy are: 
Hepatitis.  In patients taking INH, hepatitis occurs with increasing frequency 
age. In over 11,000 patients receiving INH in a public health clinic, Nolan reported a 
hepatiti
 
13 Rifabutin may be substituted for rifampin in HIV/AIDS patients who are being treated with some anti-retroviral therapy 
regimens (see Question 15). 
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http://jama.ama-assn.org).  Only clinical monitoring for symptoms and signs 
suggestive of hepatitis (loss of appetite, fatigue, malaise, nausea, RUQ abdominal 
discomfort, fever, dark urine, jaundice) was used in this study. Hepatitis was 
confirmed by liver function tests. All patients recovered with prompt cessation of the 
drug.   
Most patients can be followed without baseline or routine follow-up liver function 
tests if they are educated appropriately and can be closely monitored clinically and 
questioned at least monthly about symptoms. With the onset of any new symptom
patients should be clearly instructed 
- 
s, 
to first stop INH and then call their provider for 
further instructions. The rare fatalities associated with INH hepatitis have been 
associated with continued INH ingestion, despite hepatitis symptoms. Indications for 
baseline and periodic biochemical monitoring include patients over age 35 or with 
known abnormal liver function, known liver disease, or a history of hepatitis
factors that predispose to hepatitis, 
 or 
such as alcoholism, injection drug use, and use of 
 
s 
ceed 
-
not 
• ffects, 
 
 rifamycins induce 
mportant drugs, 
incl
s), 
prescription drugs associated with hepatitis, including prior liver toxicity from INH.
Up to 20% of people who receive INH will experience mild, asymptomatic elevation
in serum transaminases. INH should be stopped when transaminase elevations ex
5 times normal in the absence of symptoms, or 3 times normal if symptoms 
suggestive of hepatitis are present. 
- Peripheral neuritis. Uncommon among patients taking daily isoniazid (5 mg/kg/day) 
who are not receiving supplemental pyridoxine (vitamin B6). However, vitamin B6 (10
50 mg daily) is recommended for pregnant women and for anyone whose intake of 
vitamin-rich foods is questionable (e.g., alcoholics). Most public health TB clinics do 
routinely prescribe pyridoxine, in an effort to keep treatment as simple as possible.   
Rifampin:  Although rifamycins have been associated with a wide range of side e
including hepatitis, neutropenia, and a flu-like syndrome, these complications are not 
common. Compared to INH, rifampin causes less hepatitis and has the best safety profile
of the major anti-tuberculous agents. However, rifampin and other
hepatic microsomal enzymes and often accelerate metabolism of other i
uding methadone, birth control pills and hormonal implants, coumadin, some 
antihypertensives, and many others. The mutual interactions of protease inhibitors (PI
nonnucleoside reverse transcriptase inhibitors (NNRTIs), and rifamycins is discussed in 
detail in a recent CDC announcement available on the internet at 
http://www.cdc.gov/nchstp/tb/tb_hiv_drugs/toc.htm. (see footnote 5).  
In general, no (NOTE, ATS does recommend baseline CBC and platelets)  baseline or 
routine biochemical or hematologic monitoring is recommended for persons who are 
rece ed 
atients who are placed on treatment for LTBI should receive rigorous education 
about the purpose of treatment and its potential risks, including possible side effects of 
ld 
be instructed to stop the medication immediately should any adverse effect of the 
medication be suspected and then to notify the provider.  
iving rifampin, but the performance of other therapeutic agents should be monitor
during and after rifampin therapy.  Should symptoms develop, biochemical or 
hematologic testing is indicated. Monthly clinical monitoring is recommended for the 4-
month rifampin regimen.   
 
P
the medication. Relevant literature for patients are available from MDPH. Patients shou
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Question 16:  How much treatment of LTBI can be missed before the patient must sta
over? 
 
This question applies to all 3 regimens. Ideally, patients should take the equivalent of the entir
treatment course, even if additional time is needed due to interruptions. Some clinical judgment 
is needed, since clinical trial data are not available to support the efficacy of the countless 
possible patterns of drug ingestion. For the 9-month INH regimen, at least 270 doses should b
ingested within 12 months. For the 6-month INH regimen, at least 180 doses should be in
within 9 months. Finally, for the rifampin regim
rt 
e 
e 
gested 
en, at least 120 doses should be administered 
ithin 6 months. With any regimen, clinical re-evaluation is indicated for interruptions of greater 
atment should be restarted only once and then re-evaluated if non-adherence re-
ccurs.  The indications for LTBI treatment are important factors in deciding how many 
 
s 
rstand its significance. Patients should be instructed to seek medical care if they develop 
gns and/or symptoms of active TB, such as an unexplained cough that lasts more than 2 weeks, 
 complete a course of 
eatment for LTBI require no further follow-up and should be given a record of their status. 
 
 
Question 18:  When should I seek consultation with a specialist? 
 
Prim
disease specialist with experience in tuberculosis management, for the following reasons: 
• I in pregnancy. 
omplex therapy for HIV. 
ntact of a known drug-
resistant case). 
• Diagnosis and management of active TB, including interpretation of mycobacteriology 
laboratory data. 
 interactions. 
• Cultural/ethnic, or other barriers to TB prevention are identified. 
w
than 2 months.  In patients who demonstrate non-adherence where DOT is not indicated or 
available, tre
o
treatment attempts are warranted in each case.  
 
Question 17:  If a patient will not or cannot take treatment for LTBI, what is appropriate 
follow-up? 
 
Patients who cannot, or will not, take treatment for LTBI generally are not followed clinically 
for development of active TB.  Neither periodic clinical exams nor periodic chest x-rays has
been shown to be effective in detecting TB disease(reactivation tuberculosis) before symptom
develop, and neither is recommended.  Patients should keep a record of their positive TST and 
unde
si
and to remind their provider of their positive TST status. Patients who
tr
"Routine," periodic chest x-rays are not indicated in the absence of signs or symptoms of active
TB. 
ary care providers are encouraged to request consultation with a pulmonary or infectious 
 
Treatment of LTB
• Treatment of LTBI in patients receiving c
• Treatment of LTBI or active TB when drug resistance is likely (co
• TB drug complications and
 
 
 
III. Public Health Aspects 
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Question 19:  Is LTBI reportable to the state health department? 
ctive TB patients and patients suspected of active TB also are reportable by law, even if a final 
e to the 
assachusetts Department of Public Health Division of TB Prevention and Control 24 hours 
g 
rally-
rgeted outreach educator staff. For LTBI, initial evaluation, medications, and essential 
boratory monitoring are provided.  Consultation for private physicians treating cases of active 
B and LTBI is another service of the Massachusetts Department of Public Health.  Dr. John 
ernardo, the State Tuberculosis Control Officer, can be reached at 617-983-6970 (State TB 
revention and Control Program), 617-  339-7281 (pager), or by email: jbernard@bu.edu
  
Latent TB Infection now is reportable to the state health department in Massachusetts.  The LTBI 
Reporting Number (by Fax) is 617-983-6813.  Reporting forms can be obtained from the 
Massachusetts Department of Public Health, Integrated Surveillance and Informatics Services 
(ISIS). 
A
diagnosis of TB is yet not established. Cases and suspect cases are reported by telephon
M
daily by calling 1-888-MASSMTB (1-888-627-7682).  
 
 
Question 20:  What public health resources are available to my patients and me? 
 
The Massachusetts Department of Public Health Division of Tuberculosis Prevention and 
Control, in cooperation with local health departments, provides comprehensive care for persons 
with TB in Massachusetts.  State-supported TB clinics in health care facilities across 
Massachusetts offer medical expertise, radiography, mycobacteriology, and TB therapy free of 
charge to the patient for both LTBI and disease. Contact investigations of infectious cases, 
source case investigations, patient and family education, hospital discharge planning, and 
directly observed therapy are essential public health services provided by the Department of 
Public Health. For active TB cases, case management is the shared responsibility of the treatin
physician and the local and state public health nurses, and, if necessary, the support of cultu
ta
la
T
B
P . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 1:  CHILDREN WHO SHOULD BE TESTED FOR TUBERCULOSIS 
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A child who has been infected with tuberculosis (TB) may show no outward symptoms.  
However, infection can later lead to severe illness.  To detect the problem before a child 
becomes ill, we perform a tuberculosis skin test. 
Instead of testing d that only some 
hildren should have a skin test.  If a test is warranted, the child will be tested with the 
longer recommend use skin tests, such as the 
ine or Mono-vacc. 
♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦ 
ermine if your child needs to be skin tested, 
ion : 
 
 
 
           YES   NO  
 
• Has your child lived with or spent time with anyone     
who possibly or definitely had tuberculosis? 
 
• ’s household have a    
positive skin test for tuberculosis?  
 
 
• Did you (parent or guardian), your child, or anyone   
else living in your household come to the United 
country for more than a month?   
     
 your child has had a positive skin test for tuberculosis in the past, inform your child’s 
ealth care provider.  Your child will not need another test. 
ppendix 2: Treatment of Latent Tuberculosis Infection Reference 
ard 
 
 all children as we have in the past, we recommen
c
intermediate PPD (Mantoux) skin test, because it is the most accurate available.  We no 
of the less accurate multiple puncture 
T
 
 
To help your child’s health care provider det
please answer the following quest s
 
 
Does anyone living in the child
States from another country? 
 
• Has your child traveled to or lived in another 
 
 
  
If
h
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A
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The Treatment of Latent Tuberculosis Reference Card is available from 
www.umdnj.edu/globaltb
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ppendix 3: Evaluation of Program Performance Treatment of Latent A
Tuberculosis Infection  
 
The primary purpose of tuberculosis skin testing of healthy children and adults is to identify 
those with latent infection whose future risk of active disease can be reduced by preventive 
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treatment.  Preventing active tuberculosis also decreases the risk of the spread of tuberculosi
others.  The prospect of tuberculosis elimination will be enhanced. 
s to 
maintain its 
wn statistics that can serve as the basis for monitoring and continually improving performance.  
tatistics should be calculated every three months and annually.  These statistics should be 
ntive 
isk of exposure to tuberculosis should be determined for every patient on entry into the health 
care system and at regular intervals thereafter.  Depending on circumstances, a health care 
rovider may decide to determine risk of tuberculosis exposure through individual clinical 
history taken or by administering a formal tuberculosis risk questionnaire (Section I, Appendix 
1).  Def  Centers for 
Disease  and the Massachusetts 
Departm nt of Public Health. 
Performance Measure 
Proportion Screened  =  Number of People Screened for Tuberculosis Risk
 
In order to be effective, a program of testing and treatment of latent tuberculosis infection 
(LTBI) requires completion of a number of steps, and the success of each step can be defined by 
a quantitative performance measure.  Each office, health center, and clinic should 
o
S
available for inspection by the Massachusetts Department of Public Health. 
 
At some future time, a tuberculosis performance measure might be added to current Health Plan 
Employer Data and Information Set (HEDIS) parameters used to assess the quality of preve
health care, such as childhood immunization, Pap smear, and mammogram rates. 
 
 
Step 1: Identify People at High Risk for Tuberculosis Infection 
 
R
p
inition of risk categories should be according to the recommendations of the
 Control and Prevention, the American Academy of Pediatrics,
e
 
 
 
                                                            Number of People Seen 
 
 
  
 
Step 2: Test People at High Ri  Infection 
The Mantoux test (intermediate PPD), (5 TU), not multiple puncture tests (such as Tine and 
Mono-Vacc
 
 
 
Performance Measure 
ber of High Risk People Tested
sk for Tuberculosis
 
), must be used. 
 
    
 Proportion Tested  =  Num
                                 Number of High Risk People Identified 
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Step 3: Read Skin Test Results 
All tests results, positive or negative, d health care personnel.  Tests 
ould be read between 48 and 72 hours after administration.  The diameter of induration, not 
redness, is the basis of the reading.  Test results should be measured in millimeters and 
inter by the Centers for 
Dise assachusetts 
Department of Public Health.  
Performance Measure 
                                  Proportion of Tests Read  =  Number of Tests Read
 
 must be read by qualifie
sh
preted as “positive” or “negative” according to the criteria recommended 
ase Prevention and Control, the American Academy of Pediatrics, and the M
 
 
 
                                                                              Number of People Tested 
 
 
 
Steps 4: Obtain Chest Film for People with Positive Tuberculosis Skin Tests 
 
P hest film.  A 
chest film is needed to distinguish latent tuberculosis infection from active disease. 
Performance Measure 
    
         Proportion of  People with =  Number of Positive People Who have Chest Films
 
eople with a positive tuberculosis skin test should have a medical evaluation and c
 
 
      Positive Tuberculosis Skin Test           Number of People with Positive Tests 
 
 
 
 
 
 
 
 
 
